Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena
Renato V. Iozzo, James D. San Antonio
Renato V. Iozzo, James D. San Antonio
Published August 1, 2001
Citation Information: J Clin Invest. 2001;108(3):349-355. https://doi.org/10.1172/JCI13738.
View: Text | PDF
Perspective

Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena

  • Text
  • PDF
Abstract

Authors

Renato V. Iozzo, James D. San Antonio

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Heterogeneity in structure of pericellular and cell-associated heparan s...
Heterogeneity in structure of pericellular and cell-associated heparan sulfate proteoglycans with pro- and antiangiogenic activity. Syndecans are transmembrane proteoglycans, while glypicans are bound to the plasma membrane via a phosphoinositol linkage. Type XVIII collagen, a hybrid collagen/proteoglycan molecule, is a member of the multiplexin gene family characterized by alternating collagenous (thin lines) and noncollagenous domains (rectangles, not drawn in scale). Perlecan is a modular proteoglycan with five distinct domains. Both type XVIII collagen and perlecan are secreted products but are in close association with the cell surface and are intrinsic components of most basement membranes. Agrin, another HSPG with similarities to perlecan, is not shown. Glycosaminoglycan chains are shown as fuchsia-colored beaded strings and are not drawn to scale relative to their respective protein cores. The precise location and number of the heparan sulfate chains on type XVIII collagen are not known.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts